FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387249519> ?p ?o ?g. }

• W4387249519 endingPage "A775" @default.
• W4387249519 startingPage "A775" @default.
• W4387249519 abstract "SESSION TITLE: Pneumonia: New Drugs, Old Bugs, and Other Things for Your Consideration SESSION TYPE: Rapid Fire Original Inv PRESENTED ON: 10/10/2023 12:55 pm - 01:40 pm PURPOSE: New treatment options for CABP with promising activity and improved tolerability are needed. Lefamulin, a new pleuromutilin antibiotic agent, is active against common CABP pathogens. The third of 3 phase III Lefamulin Evaluation Against Pneumonia studies, LEAP-China (CTR20191226) is a multicenter, randomized, double-blind, bridging trial to assess the efficacy, safety of lefamulin in Chinese adults with CABP. It was designed to show consistency with LEAP 1, an IV-to-oral switch study in patients with PORT Risk Class III-V. METHODS: Adults with CABP were randomized 2:1 to receive lefamulin 150 mg IV Q12 hours or moxifloxacin 400 mg IV Q24 hours. Qualifying patients could be switched to oral therapy after 6 doses. The primary endpoints included investigator assessment of clinical response (IACR) in modified intent-to-treat (mITT) population at test of cure (TOC, 5-10 days after last dose of study drug). Early clinical response (ECR) at 96 hours (within 24-hour window) after receipt of first drug dose in the intent-to-treat (ITT) population and IACR of clinically evaluable (CE) population at TOC were included in the secondary endpoints. For the primary endpoints, consistency was concluded if the point estimate was >-12.5% for the difference between the two groups. RESULTS: There were 124 patients randomized (n = 82 lefamulin; n = 42 moxifloxacin) in the mITT population. The rates of IACR at TOC were 76.8% (63/82) with lefamulin vs 71.4% (30/42) with moxifloxacin in mITT population (difference 5.4%, 95% CI: -12.8 to 23.6). The point estimate of differences between the treatment groups surpassed the established objective of -12.5%, which demonstrated consistency with results of LEAP 1 study and the success of bridging. Similar rates of IACR at TOC were recorded for CE population (86.0% [49/57] with lefamulin vs 86.2% [25/29] with moxifloxacin; difference -0.2%, 95% CI: -18.3 to 17.8). The ECR responder rates in ITT population were 60.2% (50/83) with lefamulin vs 64.3% (27/42) with moxifloxacin (difference -4.0%, 95% CI: -23.7 to 15.7). Both agents demonstrated similar ECR responder and IACR success rates across baseline CABP pathogens. Rates of serious adverse events (SAEs) were 3.7% for lefamulin and 9.5% for moxifloxacin. Most frequently reported treatment-emergent adverse events (TEAEs) were infusion site reactions, the majority of mild severity with no discontinuation. CONCLUSIONS: This bridging trial met the consistency criteria with LEAP 1, supporting the noninferiority conclusion of lefamulin to moxifloxacin. The frequency of TEAEs was comparable between the two groups. CLINICAL IMPLICATIONS: Lefamulin is a promising new option as empirical monotherapy for Chinese adults with CABP. DISCLOSURES: No relevant relationships by Haihui Huang No relevant relationships by Rae Yuan No relevant relationships by Yingyuan Zhang No disclosure on file for Jie Ding No disclosure on file for Hirokazu Matsukami" @default.
• W4387249519 created "2023-10-03" @default.
• W4387249519 creator A5000234429 @default.
• W4387249519 creator A5003874489 @default.
• W4387249519 creator A5030342643 @default.
• W4387249519 creator A5061872844 @default.
• W4387249519 creator A5071255673 @default.
• W4387249519 date "2023-10-01" @default.
• W4387249519 modified "2023-10-03" @default.
• W4387249519 title "EFFICACY AND SAFETY OF LEFAMULIN IN CHINESE ADULTS WITH COMMUNITY-AQUIRED BACTERIAL PNEUMONIA (CABP): RESULTS OF LEFAMULIN EVALUATION AGAINST PNEUMONIA (LEAP-CHINA) STUDY" @default.
• W4387249519 doi "https://doi.org/10.1016/j.chest.2023.07.574" @default.
• W4387249519 hasPublicationYear "2023" @default.
• W4387249519 type Work @default.
• W4387249519 citedByCount "0" @default.
• W4387249519 crossrefType "journal-article" @default.
• W4387249519 hasAuthorship W4387249519A5000234429 @default.
• W4387249519 hasAuthorship W4387249519A5003874489 @default.
• W4387249519 hasAuthorship W4387249519A5030342643 @default.
• W4387249519 hasAuthorship W4387249519A5061872844 @default.
• W4387249519 hasAuthorship W4387249519A5071255673 @default.
• W4387249519 hasBestOaLocation W43872495191 @default.
• W4387249519 hasConcept C126322002 @default.
• W4387249519 hasConcept C168563851 @default.
• W4387249519 hasConcept C197934379 @default.
• W4387249519 hasConcept C202953159 @default.
• W4387249519 hasConcept C203092338 @default.
• W4387249519 hasConcept C2776102371 @default.
• W4387249519 hasConcept C2777914695 @default.
• W4387249519 hasConcept C2778375690 @default.
• W4387249519 hasConcept C2778836808 @default.
• W4387249519 hasConcept C2908647359 @default.
• W4387249519 hasConcept C501593827 @default.
• W4387249519 hasConcept C535046627 @default.
• W4387249519 hasConcept C71924100 @default.
• W4387249519 hasConcept C86803240 @default.
• W4387249519 hasConcept C89423630 @default.
• W4387249519 hasConcept C99454951 @default.
• W4387249519 hasConceptScore W4387249519C126322002 @default.
• W4387249519 hasConceptScore W4387249519C168563851 @default.
• W4387249519 hasConceptScore W4387249519C197934379 @default.
• W4387249519 hasConceptScore W4387249519C202953159 @default.
• W4387249519 hasConceptScore W4387249519C203092338 @default.
• W4387249519 hasConceptScore W4387249519C2776102371 @default.
• W4387249519 hasConceptScore W4387249519C2777914695 @default.
• W4387249519 hasConceptScore W4387249519C2778375690 @default.
• W4387249519 hasConceptScore W4387249519C2778836808 @default.
• W4387249519 hasConceptScore W4387249519C2908647359 @default.
• W4387249519 hasConceptScore W4387249519C501593827 @default.
• W4387249519 hasConceptScore W4387249519C535046627 @default.
• W4387249519 hasConceptScore W4387249519C71924100 @default.
• W4387249519 hasConceptScore W4387249519C86803240 @default.
• W4387249519 hasConceptScore W4387249519C89423630 @default.
• W4387249519 hasConceptScore W4387249519C99454951 @default.
• W4387249519 hasIssue "4" @default.
• W4387249519 hasLocation W43872495191 @default.
• W4387249519 hasOpenAccess W4387249519 @default.
• W4387249519 hasPrimaryLocation W43872495191 @default.
• W4387249519 hasRelatedWork W2002033312 @default.
• W4387249519 hasRelatedWork W2107697672 @default.
• W4387249519 hasRelatedWork W2133861228 @default.
• W4387249519 hasRelatedWork W22447424 @default.
• W4387249519 hasRelatedWork W2262893741 @default.
• W4387249519 hasRelatedWork W2354665811 @default.
• W4387249519 hasRelatedWork W2367272026 @default.
• W4387249519 hasRelatedWork W2378290428 @default.
• W4387249519 hasRelatedWork W2386573212 @default.
• W4387249519 hasRelatedWork W2413481398 @default.
• W4387249519 hasVolume "164" @default.
• W4387249519 isParatext "false" @default.
• W4387249519 isRetracted "false" @default.
• W4387249519 workType "article" @default.